Bemcentinib in combination with pembrolizumab demonstrated clinical efficacy in the stage 1 portion of a phase II trial, which evaluated the combination in patients with non–small cell lung cancer who progressed on prior immune checkpoint inhibition, meeting the primary end point of the study.